eslicarbazepine acetate has been researched along with naloxone in 1 studies
Studies (eslicarbazepine acetate) | Trials (eslicarbazepine acetate) | Recent Studies (post-2010) (eslicarbazepine acetate) | Studies (naloxone) | Trials (naloxone) | Recent Studies (post-2010) (naloxone) |
---|---|---|---|---|---|
229 | 68 | 175 | 20,134 | 1,257 | 3,321 |
Protein | Taxonomy | eslicarbazepine acetate (IC50) | naloxone (IC50) |
---|---|---|---|
Cytochrome P450 2D6 | Homo sapiens (human) | 2 | |
Delta-type opioid receptor | Mus musculus (house mouse) | 0.043 | |
Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0219 | |
Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0019 | |
Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0019 | |
Mu-type opioid receptor | Homo sapiens (human) | 0.0397 | |
Delta-type opioid receptor | Homo sapiens (human) | 0.1896 | |
Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.05 | |
Kappa-type opioid receptor | Homo sapiens (human) | 0.0795 | |
Mu-type opioid receptor | Mus musculus (house mouse) | 0.0154 | |
Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.0089 | |
Beta-2 adrenergic receptor | Cavia porcellus (domestic guinea pig) | 0.0055 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Micov, A; Pecikoza, U; Stepanović-Petrović, R; Tomić, M | 1 |
1 other study(ies) available for eslicarbazepine acetate and naloxone
Article | Year |
---|---|
Eslicarbazepine acetate reduces trigeminal nociception: Possible role of adrenergic, cholinergic and opioid receptors.
Topics: Adrenergic Antagonists; Analgesics; Animals; Atropine; Cholinergic Antagonists; Dibenzazepines; Formaldehyde; Male; Mice; Naloxone; Narcotic Antagonists; Pain; Receptors, Adrenergic; Receptors, Cholinergic; Receptors, Opioid; Trigeminal Neuralgia; Yohimbine | 2018 |